CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes

Randomized placebo-controlled study Assessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular function Supported by Breakthrough T1D and ongoing at University of Virginia School...